Klivira
Request demo

Navigating Kesimpta Prior Authorization for Gastroenterology Workflows

While Kesimpta prior authorization is a significant concern in other specialties, its presence in typical gastroenterology workflows is minimal. Klivira focuses on the high-volume prior authorization needs specific to GI, ensuring efficient processing for common biologics and procedures.

Revenue cycle directors and prior authorization coordinators in gastroenterology practices face substantial administrative burdens. From chronic IBD biologics to complex diagnostic procedures, the volume and complexity of prior authorizations demand specialized solutions. Understanding the specific PA landscape, even for drugs not typically in the GI formulary, is key to optimizing operational efficiency.

The Prior Authorization Landscape in Gastroenterology

Gastroenterology practices navigate a complex prior authorization environment, driven by the chronic nature of many GI conditions and the high cost of advanced therapies and diagnostic procedures. Efficient management of these authorizations is critical to patient access and revenue integrity, impacting everything from IBD biologics to advanced imaging.

High-Volume Prior Authorization Categories in GI

  • IBD biologics (e.g., TNF inhibitors, integrin inhibitors, IL-12/23 inhibitors)
  • Hepatitis C direct-acting antivirals (DAAs)
  • Advanced imaging (e.g., MRCP, MR enterography, CT enterography)
  • Endoscopic procedures with specific PA requirements (e.g., capsule endoscopy, ERCP)
  • Specialty drugs for functional GI disorders

Documentation Requirements and Clinical Guidelines for GI Biologics

Payer policies for GI biologics are often anchored in guidelines from the ACG, AGA, and AASLD. Approval typically hinges on comprehensive documentation, including diagnosis confirmation, disease severity assessment (e.g., Mayo score for UC, CDAI for Crohn's), prior conventional and biologic therapy trials, and essential pre-initiation screenings like TB and hepatitis.

Common Prior Authorization Denial Reasons in Gastroenterology

  • Failure to meet step therapy requirements for IBD biologics
  • Payer mandate for biosimilar substitution over brand-name biologics
  • Insufficient documentation of disease severity
  • Gaps in required pre-treatment screening documentation (e.g., TB, hepatitis)
  • Inappropriate-use criteria for advanced imaging requests

Addressing Drug-Specific Prior Authorization: Kesimpta in Context

Klivira's platform is designed to manage prior authorizations across all specialties and drug categories. While Kesimpta (ofatumumab) is primarily indicated for conditions outside of typical gastroenterology practice, such as multiple sclerosis, Klivira's robust payer policy engine is equipped to process its prior authorization requirements should it arise in an atypical clinical scenario. Our focus for gastroenterology, however, remains on the high-volume biologics, specialty drugs, and procedures central to GI care.

Klivira's Platform for Gastroenterology Prior Authorization

Klivira’s automation platform streamlines GI prior authorizations by integrating directly with EMRs and payer portals. We provide ACG/AGA-guideline-aware step therapy logic for IBD biologics, automate treatment-status classification from medication histories, and manage the complex periodic re-authorization workflows essential for chronic GI treatments. Our system also intelligently routes medical-vs-pharmacy benefit PAs as administration modes change.

Frequently asked questions

Is Kesimpta commonly prescribed in gastroenterology practices?

Kesimpta (ofatumumab) is an anti-CD20 monoclonal antibody primarily indicated for relapsing forms of multiple sclerosis and is not typically prescribed within gastroenterology for conditions like inflammatory bowel disease (IBD) or other GI disorders. While Klivira's platform can manage prior authorizations for any drug, our specialized solutions for gastroenterology focus on the high-volume biologics, procedures, and specialty medications routinely encountered in GI practice.

Why is prior authorization for IBD biologics so complex in gastroenterology?

Prior authorization for IBD biologics is complex due to chronic treatment cadences requiring periodic re-authorization, stringent step therapy requirements, variability in biosimilar substitution policies across payers, and the critical distinction between treatment-naive and treatment-experienced patient pathways.

How does Klivira handle step therapy requirements for GI biologics?

Klivira's platform incorporates ACG/AGA-guideline-aware step therapy logic for IBD biologic sequencing. This ensures that the documentation submitted aligns with payer-specific requirements, such as requiring failure of conventional therapy or specific TNF inhibitor trials before non-TNF agents.

What documentation is critical for advanced imaging PAs in GI?

For advanced imaging, critical documentation includes a clear clinical question, a detailed history of prior imaging, and evidence of completed conservative workup. Payers often require specific clinical correlation to justify the medical necessity of procedures like MR enterography.

Does Klivira support both medical and pharmacy benefit prior authorizations for GI drugs?

Yes, Klivira's platform is equipped to manage prior authorizations for GI biologics administered under both medical and pharmacy benefits. This is crucial for agents that may be provider-administered infusions (medical benefit) or self-administered injections (pharmacy benefit), even for the same patient over time.

Related coverage

Other kesimpta prior authorization by payer

Other kesimpta prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo